drugset / Trial / NCT05200013
BAT7104 in Patients With Advanced Solid Tumours
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a prospective multi-centre, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients with Advanced Solid Tumours in Australia.
Timeline
- Start
- 2022-04-29
- Primary completion
- 2024-06-25
- Completion
- 2024-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAT7104 | Unknown | 0.3 mg/kg | — |
| Subject | BAT7104 | Unknown | 1 mg/kg | — |
| Subject | BAT7104 | Unknown | 3 mg/kg | — |
| Subject | BAT7104 | Unknown | 10 mg/kg | — |
| Subject | BAT7104 | Unknown | 20 mg/kg | — |
| Subject | BAT7104 | Unknown | 40 mg/kg | — |
Indications
No indication recorded.